Member Info for crumbs

So it does sound like scancell have identified 33 potential cancer targets for modi1/modi2 .... each target a potential deal both in TCR and in vaccine form .... so that is a lot of potential deals lol and a lot more moditope epitopes still to be found ...obviously we need the first one first:) but... wow!

I cant fully clearly hear everything after that but I'm sure he says identifying epitopes against 33 targets or something and Lindy goes on to say after saying BioNtech is also interested in vaccines and other companies too that there are potentially a lot more deals.... or something like that...

Cliff in Q&A yes talking about the TCRs
'It is about identifying the t cell receptors against the modi 1 epitopes so it is only modi1, being able to identify these t cell receptors is a great validator in the absence of clinical data it is a significant validator of the overall technology because if we identify these cd4 t cell receptors then that means there is a whole population of t cells that can recognise these epitopes and therefore it is much more likely they occur in patients and therefore more likely to have an effective drug'

Yeah but if 18 peptides all showing potency against cancer now honed to 5... if they can only do 3 in each modi I guess there is a possibility of a number of different versions of modi2 ... it is all mind-boggling lol but I am encouraged by what is coming out of this BioNtech collab ... like a say real pre-clinical validation and not in a mouse model only....Sahin's got to be impressed

Also with nano delivery, I think it is now far more realistic to imagine a patient at risk of metastatic disease who has had a tumour cut out being put on an ImmunoBody course of injections as a routine preventative measure etc

I think the idea is immunoBody is more an early stage platform and moditope latestage... but with all the research going on who knows how it will end up... it is amazing really it is hard to get over the importance of the validation these 40 epitopes identified in the BioNtech are... short of clinical data this is gold... it shows moditope effectively working using donated human blood able to direct CD4 killers to 40 cancer specific epitopes... using just 3 of moditopes possibly hundreds of potential peptides.... obviously now they will work through the 40 and hone down to a clinically viable product everyone (lindy and Sahin) are happy with... so yeah 6 months behind but at the end of that 6 months they could have a product ready to be taken forwards into the clinic!... going to be fascinating to watch it unfold.. and no wonder we are (possibly) reluctant to give any moditope IP away at this stage its potential value is well massive!

Also... this TCR collab... 40 epitopes from just 3 modi1 peptides.... the potential considering how many moditope peptides scancell are identifying is truly- wow!

inananco...do you think that modi2 is going to be including all the 5 best peptides that they have identified? what I'm wondering is how many peptides can a modi contain to be a viable product any ideas?

The thing with these glycan Mabs and avidimab is that they are going to be of great interest to a load of biotech/pharma anyone into MaBs is a potential deal plus they could attract CAR T players too which we all know is a very hot area

Yeah.. and there must be a reason why this collaboration is 'none exclusive' as you would think the partner that is serious enough to have this one year plan would have prefered that.... of course, it is in scancells interests that it isn't and maybe that is part of the reason the partner would rather no rival knows who they are.

Ha yeah guess it does though doubt we can bank on it:) I'd like to think BioNtech TCR or indeed move on moditope would come sooner... but it is good that we now have these potential incoming funds and that we sort of have a timescale on them as in should be happening if it does next year

That does not mean they won't do a deal anytime on it but I reckon it won't be anytime soon....no doubts doing a very thorough job so at end of it if all goes well it could be a very large deal considering there are 5 Glycan MaBs and the company will have their own Mabs (possibly lots) and if they want to use Avidimab on them all could be tastey.... I would have like to asked Lindy about the 2 companies showing serious interest in one of the MaBs back in 2015....what happened to em!

They don't want their name announced Which is deemed not unusual and they're working on it to a one year plan

I'm a bit more sceptical of that good till early 2021... if we have both trials up and fully running by h1 2020 I reckon if we haven't got incoming funds from elsewhere there will have to be a raising but hopefully, sp will be at least over 10p by then anyways there isn't an imminent need for funds at moment and there could be all kinds of positive newsflow before they are needed ....It'll be interesting to see what the 4 posters being presented in the company of Mellman and Sahin in Paris in a couple of weeks will be ....could one of them be based around the TCR research so far? or could one be about the coming modi3 dunno... but with so much going on they will bound to be exciting science

We might be all able to arrive in our private jets :) ..... I am glad that thanks to one questioner we did get to hear from Martin and again reassuring that he is looking to be here longterm.

I can't remember what moniker he posted under here but you would think he would have gotten out of scancell by now but seems he just likes to feel wronged so then he can vent... think your assessment of his performance is about right lol.... some good info came out of the Q&A but if it was left to p7 nothing would have been learnt we know we are at 7p we can all see it! :)

The MaB market is a $100 billion-plus one...... Avidimab could improve every MaB no matter what target = Huge

However nice to see the Pfizer connected name :).... there has often been an under the radar feeling here but I think we might be wrong...I think the industry may well be heading Lindy's way

Yes I think so... Lindy is mates with prof Stern

I meant look at the conflict of interest part of link I gave... no scancell conflict of interest as none of their tech involved